Skip to main content

Table 1 Characteristics of patients at baseline (before mepolizumab initiation)

From: Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series

Age (y), no 8
mean ± SD 55.75 ± 13.13
Sex, no 8
 Male, no. (%) 6
 Female, no. (%) 2
Age at diagnosis (y) 51.50 ± 12.60
BMI (Kg/m2) 24.92 ± 4.10
Asthma 8
ENT involvement 8
Polyposis, no 8
 Yes, no. (%) 7
 No, no. (%) 1
Rhinosinusitis, no 8
 Yes, no. (%) 8
 Yes, no. (%) 0
SNOT-22  
Mean ± SD 49 ± 22.9
TENPS no 8
Mean ± SD 3.4 ± 3.8
Polyposis surgery, no 8
 Yes, no. (%) 7
 No, no. (%) 1
Eosinophils (cell/mcl),
 Mean ± SD 2.384 ± 2.209
BVAS
 Mean ± SD 21.75 ± 6.41
ACT
 Mean ± SD 8.3 ± 2.7
FEV1%
 Mean ± SD 73 ± 24.5
Prednisone intake
Mean ± SD 16.7 ± 9
Pulmonary infiltrates 5
Peripheral nervous system involvement 3
Arthralgia/arthritis 6
Cardiac involvement 1
Glomerulonephritis 0
Ocular involvement 1
Skin involvement 4
ANCA positivity patients 2
Present and Previous treatments  
OCS 7
 Azathioprine 2
 Intravenous cyclophosphamide 2
 Methotrexate 0
 Mycophenolate mofetil 2
 Omalizumab 2
  1. BMI Body mass index, SNOT-22 Sino-Nasal Outcome Test, TENPS Total endoscopic polyp score, BVAS Birmingham vasculitis activity score, ACT Astma control test, FEV1% forced expiratory volume at 1 s (%), ANCA antineutrophil cytoplasm antibodies, OCS oral corticosteroids